# Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

> **NCT01383447** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** entinostat
- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **GENETIC:** western blotting
- **OTHER:** immunohistochemistry staining method
- **OTHER:** flow cytometry
- **GENETIC:** polymerase chain reaction
- **OTHER:** high performance liquid chromatography
- **OTHER:** mass spectrometry

## Key facts

- **NCT ID:** NCT01383447
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** This study was halted prematurely by the NCI for low accrual.
- **Last updated:** 2017-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01383447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01383447, "Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01383447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*